Pyrazolopyridine Derivatives for WIZ Reduction and HbF Induction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for sickle cell disease and beta-thalassemia, such as hydroxyurea, are genotoxic and have limited efficacy, with less than 40% response rate, while other mechanisms like HDAC1/2, LSD1, DNMT1, PDE9a, HRI kinase, and G9a/GLP inhibitors are being explored but have varying clinical success.
Innovation Solution
Development of pyrazolopyridine derivatives that reduce WIZ protein expression and induce fetal hemoglobin (HbF) expression, providing a novel therapeutic approach for these disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If hydroxyurea is used to induce HbF, then HbF expression is increased, but genotoxicity and neutropenia occur with limited efficacy
Solution Approach 1:
The patent changes the chemical parameter from hydroxyurea to pyrazolopyridine derivatives, which have different molecular structures and mechanisms of action. This parameter change allows achieving HbF induction while avoiding the genotoxicity and neutropenia associated with hydroxyurea
Solution Approach 2:
The patent employs small molecule pyrazolopyridine derivatives that can be administered systemically and eliminated without accumulating long-term toxicity, unlike hydroxyurea which causes persistent genotoxic effects and bone marrow suppression
2Reliability
If hydroxyurea is used to treat sickle cell disease, then some patients experience benefit, but response rate is less than 40%
Solution Approach 1:
The patent changes the therapeutic parameter from hydroxyurea to pyrazolopyridine derivatives that target different molecular pathways (WIZ protein inhibition). This parameter change addresses the variability in patient response by providing an alternative mechanism that may be effective in hydroxyurea-nonresponders
Solution Approach 2:
The patent introduces pyrazolopyridine derivatives as intermediary compounds that inhibit WIZ protein, which in turn induces HbF expression. This intermediary mechanism provides a different pathway to achieve the same therapeutic goal, potentially expanding the patient population that can benefit from treatment
Data Source
AI summary
The present disclosure relates to compounds of formula (I) and pharmaceutical compositions and their use in reducing Widely Interspaced Zinc Finger Motifs (WIZ) expression levels, or inducing fetal hemoglobin (HbF) expression, and in the treatment of inherited blood disorders (e.g., hemoglobinopathies, e.g., beta-hemoglobinopathies), such as sickle cell disease and beta-thalassemia.